[go: up one dir, main page]

BR112014010542A2 - métodos e composições para tratamento de ferimento - Google Patents

métodos e composições para tratamento de ferimento

Info

Publication number
BR112014010542A2
BR112014010542A2 BR112014010542A BR112014010542A BR112014010542A2 BR 112014010542 A2 BR112014010542 A2 BR 112014010542A2 BR 112014010542 A BR112014010542 A BR 112014010542A BR 112014010542 A BR112014010542 A BR 112014010542A BR 112014010542 A2 BR112014010542 A2 BR 112014010542A2
Authority
BR
Brazil
Prior art keywords
methods
average molecular
scar
treatment
compositions
Prior art date
Application number
BR112014010542A
Other languages
English (en)
Inventor
G Lowe Adam
Michael Green Andrew
Prudhomme Kathleen
Yamamoto Ronald
Nguyen Tien
Original Assignee
Halscion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halscion Inc filed Critical Halscion Inc
Publication of BR112014010542A2 publication Critical patent/BR112014010542A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0038—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

abstract the present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scarring or keloid formation. the composition includes gelatin having an average molecular mass of about 75,000 da to about 250,000 da and a polymeric carbohydrate having an average molecular mass of about 10,000 da to about 1,000,000 da. the invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods. tradução do resumo resumo patente de invenção: "métodos e composições para tratamento de ferimento". a presente invenção proporciona composições e métodos úteis no tratamento de ferimentos, particularmente na redução ou prevenção de formação de cicatriz, particularmente cicatriz hipertrófica, ou formação de quelóide. a composição inclui gelatina tendo uma massa molecular média de cerca de 75.000 da a cerca de 250.000 da, e um carboidrato polimérico tendo uma massa molecular média de cerca de 10.000 da a cerca de 1.000.000 da. a invenção, desse modo, proporciona adicionalmente métodos de tratamento, incluindo métodos úteis na revisão de cicatriz hipertrófica ou quelóide, bem como métodos de inibição de cicatriz profiláticos.
BR112014010542A 2011-11-02 2012-11-01 métodos e composições para tratamento de ferimento BR112014010542A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161554870P 2011-11-02 2011-11-02
PCT/US2012/063083 WO2013067195A1 (en) 2011-11-02 2012-11-01 Methods and compositions for wound treatment

Publications (1)

Publication Number Publication Date
BR112014010542A2 true BR112014010542A2 (pt) 2017-04-18

Family

ID=47146773

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010542A BR112014010542A2 (pt) 2011-11-02 2012-11-01 métodos e composições para tratamento de ferimento

Country Status (8)

Country Link
US (1) US9561247B2 (pt)
EP (1) EP2776052B1 (pt)
JP (1) JP2014532713A (pt)
KR (1) KR20140097256A (pt)
CN (1) CN104080468A (pt)
BR (1) BR112014010542A2 (pt)
CA (1) CA2854160A1 (pt)
WO (1) WO2013067195A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005391A1 (en) * 2013-06-26 2015-01-01 COLE Research & Design, Inc. Method of reducing scarring
US9585943B2 (en) 2014-02-03 2017-03-07 George D. Petito Composition for tissue/cell repair
US9125892B2 (en) 2014-02-03 2015-09-08 George D. Petito Composition for reduced scar formation of wounds
WO2016123693A1 (en) 2015-02-06 2016-08-11 The University Of British Columbia Engineered tissue substitute system
WO2017112757A1 (en) * 2015-12-23 2017-06-29 Shire Human Genetic Therapies, Inc. Collagen 7 compositions and methods of using the same
US10099995B2 (en) 2015-12-24 2018-10-16 Cole Research and Design, LLC Resveratrol esters
EP3675874B1 (en) * 2017-09-01 2023-11-29 Excel Med, LLC Pharmaceuticals composition for treating keloid and uses thereof
ES2953184T3 (es) * 2018-03-09 2023-11-08 Carmeda Ab Mejoras en procesos de inmovilización de entidades biológicas
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
CN108904859A (zh) * 2018-07-23 2018-11-30 衢州玛济克医疗科技有限公司 一种痔疮医用敷料及其生产方法
CZ308845B6 (cs) * 2019-01-21 2021-07-07 Globetech Innovation S.R.O Farmaceutická směs topicky hojivých peptidových složek pro použití k topické léčbě kožních defektů a/nebo k topickému hojení ran

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280954A (en) 1975-07-15 1981-07-28 Massachusetts Institute Of Technology Crosslinked collagen-mucopolysaccharide composite materials
US4618490A (en) 1980-06-06 1986-10-21 Marco Peter T De Method of treatment of animal and human tissues damaged by burns and frank visible gangrene
SU1002356A1 (ru) 1980-12-31 1983-03-07 Всесоюзный кардиологический научный центр АМН СССР Способ получени иммобилизованного фибринолизина
US4520821A (en) 1982-04-30 1985-06-04 The Regents Of The University Of California Growing of long-term biological tissue correction structures in vivo
GB2148901A (en) 1983-10-04 1985-06-05 Johnson & Johnson Protein/polysaccharide complexes
GB8328074D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compositions
US4837024A (en) 1984-02-24 1989-06-06 The Regents Of The University Of California Compositions, articles and mehtod for improving wound healing
US4863856A (en) 1985-04-04 1989-09-05 Verax Corporation Weighted collagen microsponge for immobilizing bioactive materials
US4997753A (en) 1985-04-04 1991-03-05 Verax Corporation Weighted collagen microsponge for immobilizing bioactive material
US5100783A (en) 1985-05-10 1992-03-31 Verax Corporation Weighted microsponge for immobilizing bioactive material
US4895724A (en) 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
EP0213908A3 (en) 1985-08-26 1989-03-22 Hana Biologics, Inc. Transplantable artificial tissue and process
US4902295A (en) 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
JPS62246371A (ja) 1986-04-19 1987-10-27 株式会社　高研 人工皮膚及びその製造方法
US4965203A (en) * 1987-01-28 1990-10-23 Warner-Lambert Company Purified thrombin preparations
US5705485A (en) 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5350583A (en) 1988-03-09 1994-09-27 Terumo Kabushiki Kaisha Cell-penetrable medical material and artificial skin
EP0403650B1 (en) 1988-03-09 1994-05-25 Terumo Kabushiki Kaisha Medical material permitting cells to enter thereinto and artificial skin
US4950483A (en) 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5800541A (en) 1988-11-21 1998-09-01 Collagen Corporation Collagen-synthetic polymer matrices prepared using a multiple step reaction
US5306500A (en) 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5510418A (en) 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US4957902A (en) 1988-12-20 1990-09-18 Board Of Regents, The University Of Texas System Peptide inhibitors of wound contraction
US5073373A (en) 1989-09-21 1991-12-17 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
US5290558A (en) 1989-09-21 1994-03-01 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US5466609A (en) 1990-10-31 1995-11-14 Coulter Corporation Biodegradable gelatin-aminodextran particle coatings of and processes for making same
US5099012A (en) 1990-12-11 1992-03-24 Eastman Kodak Company Chroman-2-carboxamide conjugates and their use for treatment of reperfusion injury
CS277533B6 (en) 1990-12-29 1993-03-17 Krajicek Milan Fixed osteaosynthesis appliance
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5591709A (en) 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US6352707B1 (en) 1992-02-24 2002-03-05 Anton-Lewis Usala Transplant encapsulation in a hydrogel matrix to obscure immune recognition
US5830492A (en) 1992-02-24 1998-11-03 Encelle, Inc. Bioartificial devices and cellular matrices therefor
WO1993016685A1 (en) 1992-02-24 1993-09-02 Encelle, Inc. Bioartificial endocrine device
US6231881B1 (en) 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US5834005A (en) 1992-02-24 1998-11-10 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US5824331A (en) 1992-02-24 1998-10-20 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
JPH09510182A (ja) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
US5569468A (en) 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
DE69534640T2 (de) 1994-04-29 2006-08-10 Scimed Life Systems, Inc., Maple Grove Stent mit Kollagen
US5783214A (en) 1994-06-13 1998-07-21 Buford Biomedical, Inc. Bio-erodible matrix for the controlled release of medicinals
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5733337A (en) 1995-04-07 1998-03-31 Organogenesis, Inc. Tissue repair fabric
US6833408B2 (en) 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US6132759A (en) 1996-05-03 2000-10-17 Innogenetics N.V. Medicaments containing gelatin cross-linked with oxidized polysaccharides
US5718012A (en) 1996-05-28 1998-02-17 Organogenesis, Inc. Method of strength enhancement of collagen constructs
FR2754268B1 (fr) 1996-10-07 1998-12-24 Dev Des Utilisations Du Collag Composition adhesive a base de polyaldehyde macromoleculaire et procede de reticulation de collagene ou de gelatine
US5756715A (en) 1996-11-08 1998-05-26 Abbott Laboratories Process for making crystalline iron dextran
US6011008A (en) 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
US5866165A (en) 1997-01-15 1999-02-02 Orquest, Inc. Collagen-polysaccharide matrix for bone and cartilage repair
US5972332A (en) 1997-04-16 1999-10-26 The Regents Of The University Of Michigan Wound treatment with keratinocytes on a solid support enclosed in a porous material
US5993844A (en) 1997-05-08 1999-11-30 Organogenesis, Inc. Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix
WO1998055161A1 (en) 1997-06-03 1998-12-10 Innogenetics N.V. New medicaments based on polymers composed of methacrylamide-modified gelatin
US6077916A (en) 1997-06-04 2000-06-20 The Penn State Research Foundation Biodegradable mixtures of polyphoshazene and other polymers
US6303585B1 (en) 1997-07-03 2001-10-16 Orquest, Inc. Cross-linked polysaccharide drug carrier
US5922339A (en) 1998-01-27 1999-07-13 Usala; Anton-Lewis Compositions and methods for biocompatible implants
US7045141B2 (en) 1998-02-27 2006-05-16 Musculoskeletal Transplant Foundation Allograft bone composition having a gelatin binder
EP1056836B1 (en) 1998-02-27 2009-02-18 Purdue Research Foundation Submucosa gel compositions
US6378527B1 (en) 1998-04-08 2002-04-30 Chondros, Inc. Cell-culture and polymer constructs
DE69931371T2 (de) 1998-07-10 2007-05-24 Encelle, Inc. Methoden zur verbesserung der vaskularisierung und förderung der wundheilung
EP1095159A4 (en) 1998-07-15 2003-01-02 Human Genome Sciences Inc Bone Morphogenetic Protein
GB9902652D0 (en) 1999-02-05 1999-03-31 Fermentech Med Ltd Process
US6696410B1 (en) 1999-09-27 2004-02-24 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
EP1142596A1 (en) 2000-04-03 2001-10-10 Universiteit Gent Compositions of crosslinkable prepolymers for use in therapeutically active biodegradable implants
US6682760B2 (en) 2000-04-18 2004-01-27 Colbar R&D Ltd. Cross-linked collagen matrices and methods for their preparation
AU6349501A (en) 2000-05-31 2001-12-11 Encelle Inc Method of treating chronic ulcers
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US6902881B2 (en) 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
CA2365376C (en) 2000-12-21 2006-03-28 Ethicon, Inc. Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
US20020176893A1 (en) 2001-02-02 2002-11-28 Wironen John F. Compositions, implants, methods, and kits for closure of lumen openings, repair of ruptured tissue, and for bulking of tissue
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
WO2003072155A1 (en) 2002-02-21 2003-09-04 Encelle, Inc. Cross-linked bioactive hydrogel matrices
CA2489712C (en) 2002-06-21 2016-07-12 University Of Utah Research Foundation Crosslinked compounds and methods of making and using thereof
CN101632843A (zh) 2002-08-20 2010-01-27 精密技术公司 骨生长诱导材料的携带和输送用组合物以及生产和应用该组合物的方法
PL1677846T3 (pl) * 2003-10-22 2015-02-27 Encelle Inc Kompozycje bioaktywnego hydrożelu do regenerowania tkanki łącznej
US8790632B2 (en) * 2004-10-07 2014-07-29 Actamax Surgical Materials, Llc Polymer-based tissue-adhesive form medical use
US7951393B2 (en) * 2007-11-14 2011-05-31 Canaan Vernon Lavelle Harris Keloid therapy
US20110290693A1 (en) * 2007-11-14 2011-12-01 Canaan Vernon Lavelle Harris Abnormal Scar Therapy
US20090130756A1 (en) 2007-11-20 2009-05-21 Pioneer Surgical Orthobiologics,Inc. Cryopreservation of cells using cross-linked bioactive hydrogel matrix particles
CN101260191B (zh) * 2008-04-01 2011-04-20 武汉大学 一种温度敏感型壳聚糖/明胶水凝胶及其制备方法和用途
US9066991B2 (en) * 2009-12-22 2015-06-30 Lifebond Ltd. Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
CA2825059A1 (en) 2011-02-02 2012-08-09 Excaliard Pharmaceuticals, Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)

Also Published As

Publication number Publication date
WO2013067195A1 (en) 2013-05-10
US20130108700A1 (en) 2013-05-02
EP2776052A1 (en) 2014-09-17
KR20140097256A (ko) 2014-08-06
JP2014532713A (ja) 2014-12-08
CA2854160A1 (en) 2013-05-10
CN104080468A (zh) 2014-10-01
US9561247B2 (en) 2017-02-07
EP2776052B1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
BR112014010542A2 (pt) métodos e composições para tratamento de ferimento
BR112015014592A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um humano
MX2021009667A (es) Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar.
BR112012030037A2 (pt) composição terapêutica oral
EA201690904A1 (ru) Антибактериальная композиция для ротовой полости
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
BR112012010705A2 (pt) composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio
BR112015013774A2 (pt) membrana de hidrogel para prevenção de adesão
WO2008116129A3 (en) Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
BR112012009305A2 (pt) composição de dentifrício, e, métodos para o tratamento e prevenção de acúmulo de placa bacteriana ou prevenção de erosão dentária, e para a fabricação de uma composição de dentifrício
MY160894A (en) Oligosaccharide composition for treating skin diseases
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
UA111162C2 (uk) Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
NZ602219A (en) Methods and compositions for treating degos’ disease
BR112014015940A8 (pt) composição de novo fármaco de carboidrato para tratamento de doenças humanas
HK1201213A1 (en) Nonaqueous compositions for bone hemostasis, and methods for their use and manufacture
BR112013020159A2 (pt) método para inibir células tumorais de hamartoma
BR112014009330A2 (pt) solução para administração oral
BR112013022217A8 (pt) composição farmacêutica, método de tratamento preventivo de uma síndrome hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b
EA201270186A1 (ru) Фармацевтические композиции, содержащие модифицированные фуканы, для использования при лечении фиброзных спаек и других нарушений
BR112013007343A2 (pt) métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
BR112012019921A2 (pt) composições líquidas compreendendo um agente de resfriamento não-metol e um espessante para tratamento de um sintoma respiratório.
WO2010008573A3 (en) Wound healing

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)